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Friedreich’s ataxia (FRDA) is caused by deficient expression of themitochondrial protein frataxin involved in the formation of iron-
sulphur complexes and by consequent oxidative stress.We analysed low-dose tocotrienol supplementation effects on the expression
of the three splice variant isoforms (FXN-1, FXN-2, and FXN-3) in mononuclear blood cells of FRDA patients and healthy subjects.
In FRDA patients, tocotrienol leads to a specific and significant increase of FXN-3 expression while not affecting FXN-1 and FXN-
2 expression. Since no structural and functional details were available for FNX-2 and FXN-3, 3D models were built. FXN-1, the
canonical isoform, was then docked on the human iron-sulphur complex, and functional interactions were computed; when FXN-
1 was replaced by FXN-2 or FNX-3, we found that the interactions were maintained, thus suggesting a possible biological role
for both isoforms in human cells. Finally, in order to evaluate whether tocotrienol enhancement of FXN-3 was mediated by an
increase in peroxisome proliferator-activated receptor-𝛾 (PPARG), PPARG expression was evaluated. At a low dose of tocotrienol,
the increase of FXN-3 expression appeared to be independent of PPARG expression. Our data show that it is possible to modulate
the mRNA expression of the minor frataxin isoforms and that they may have a functional role.
1. Introduction
Friedreich’s ataxia (FRDA) is themost common ataxia among
Caucasians, with an estimated incidence of 1 : 40,000 individ-
uals [1]. It is inherited as autosomal recessive disorder with
onset typically in the second decade of life. The majority of
FRDA patients suffer hypertrophic cardiomyopathy, which is
the principal cause of death [2].
The gene responsible for FRDA, FXN, located on chro-
mosome 9, is composed by seven exons (exons 1–4, 5a, 5b,
and 6) and encodes for a mitochondrial protein, frataxin.
Frataxin is expressed at much lower levels (5–30%) in FRDA
patients compared with normal individuals [3]. In 98% of
cases, frataxin downregulation is due to a homozygous GAA
trinucleotide expansion in the first intron of the FXN, which
is responsible for the transcriptional silencing of FXN gene
[4, 5].
At present, three different transcripts of FXN gene are
known. The major transcript (1.3 kb) is composed by five
exons (exons 1–4 and 5a) and encodes for a 210-amino acid
protein, named frataxin isoform A or FXN-1 (NM 000144;
NP 000135). A minor alternative transcript, frataxin isoform
B or FXN-3, containing the exon 5b in place of exon 5a
(NM 001161706) was described [4]. Due to an in-frame stop
codon in exon 5b,FXN-3mRNAencodes for a shorter protein
of 171- amino acid (NP 001155178). FXN-1 and FXN-3 pro-
teins share a sequence identity of 93%, showing a difference
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in sequence and length in the C-terminus portion. FXN-3 C-
terminus contains 11 residues instead of 48 residues of the
FXN-1 (RLTWLLWLFHP in place of SGPKRYDWTGKN-
WVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGK). In
2002, Pianese and coworkers identified a third splice variant
of frataxin, namely, frataxin isoform A1 or FXN-2. Similarly
to FXN-1, FXN-2 transcript is composed by the exons 1–4
and 5a (NM 181425) [6]. FXN-2 mRNA differs from FXN-1
mRNA for an insertion of 8 bp due to an alternative splicing
site at 5󸀠 end of intron 4. The 8 bp insertion generates a
frameshift that introduces a stop codon site, so that this
transcript encodes for a shorter protein of 196 amino acids
(NP 852090). After their first description, FXN-2 and FXN-3
transcripts were not studied in detail and no functional data
about the protein isoforms have been reported. Recently, Xia
and coworkers have identified two novel isoforms of frataxin
specifically expressed in affected cerebellum and heart [7].
Frataxin is a well-conserved and ubiquitous protein; its
expression levels are rather low, with the exception of tissues
such asmuscle, heart, and cerebellum.The three-dimensional
structure of human [8], yeast [9], and bacterial [10] frataxin
was obtained. They are strictly alike, with different elements
of secondary structure conserved. Frataxin is characterized
by a flat 𝛽-sheet platform supported by two parallel 𝛼-helices
at N andC terminus. Frataxin protein contains two structural
elements that are conserved in all frataxin orthologs: (i) the
presence of acidic residues in the first 𝛼-helix (𝛼-1) and 𝛽-
strand (𝛽-1) which form a negatively charged surface; (ii) a
neutral flat area on the 𝛽-sheet surface that probably allows
the interaction of protein partner(s) on frataxin [8].
It is known that frataxin is involved in different biological
processes such as iron binding and storage, biogenesis of
heme and of iron-sulphur (ISC/NSF1) cluster proteins, and
iron chaperone activity [11–14]. It has been shown that
frataxin is involved also in Fe detoxification, and therefore
it may play a key role in the regulation of oxidative stress
[15]. Other physiological functions of frataxin are still to be
determined.
There are no effective treatments to prevent the neurode-
generative progression of FRDA; currently, FRDA patients
regularly take idebenone, an analogue of coenzyme Q10,
which exerts its beneficial effects by ameliorating cardiac and
cerebellum function and modulating oxidative stress [16, 17].
However, recent research has shown that in a 6-month ran-
domized, double-blind, controlled study, idebenone did not
improve cardiac [18] or neurological [19] function. For that
reason, researchers focused on new molecules with higher
antioxidant, neuroprotective, and cardioprotective propri-
eties [20] and/or on agents able to increase cellular frataxin
expression [21, 22].
Tocotrienol could be a promising compound in FRDA
treatment. Tocotrienols belong to the family of vitamin E
and, unlike tocopherol, contain three double bonds in their
isoprenoid side chain and have a greater bioavailability. They
exhibit strong antioxidant, anticancer, cardioprotective, and
neuroprotective properties [23]. In a recent study, we have
shown that, in five FRDApatients treatedwith idebenone and
in five healthy volunteers, a two-month low-dose tocotrienol
supplementation led to the decrease of oxidative stress
indexes (M. Marini, submitted paper).
Anderson and colleagues have shown that tocotrienol is
able to regulate directly the expression of IKBKAP whose
alteration is responsible for a neurodegenerative disease,
familial dysautonomia [24, 25].
The aim of this study was to evaluate, in FRDA patients
regularly assuming idebenone and in healthy volunteers, the
effect of twomonths tocotrienol supplementation on frataxin
isoforms gene expression. Since frataxin is a ubiquitous pro-
tein, we evaluated its expression in mononuclear blood cells,
as previously reported [5]. Moreover, in order to understand
whether the less expressed FXN-2 and FXN-3 isoforms may
have a possible role in the cell, a 3D model of both isoforms
and a docking study between FXN-2 or FXN-3 and the
human complex NFS1/ISCU were determined.
2. Material and Methods
2.1. Patients and Healthy Subjects. Five FRDA patients and
five healthy volunteers were enrolled after signing an
informed consent form.The Child Neurology and Psychiatry
Unit, IRCCS Institute of Neurological Sciences of Bologna,
Bologna, Italy, enrolled all subjects in this study. This study
was approved by the Ethical Committee of Regional Health
Service (number 1635-08092011).
FRDA was diagnosed according to Harding 123 diagnos-
tic criteria, and the genetic test showed an altered number of
GAA repeats; in particular, the less expanded allele contains
the following number of GAA repeats: patient 1, 830; patient
2, 625; patient 3, 560; patient 4, 360; patient 5, 621. Patients
regularly assumed idebenone (5mg/kg body weight/day),
which was not discontinued during the study.
Healthy volunteers, used as control, were age and sex
matched with the FRDA patients; they were not affected by
any neurological or psychiatric disease and were not under
pharmacological treatment of any type nor were assuming
food integrators.
2.2. Experimental Design. FRDA patients and healthy con-
trols took a tocotrienol supplementation per os for two-
month. Venous blood was collected before (presubjects) and
at the end (postsubjects) of tocotrienol treatment.
Tocotrienol dose used in this study (7mg/kg bodyweight/
day) was much lower than that estimated as no observed
adverse effect level (NOEAL) in rats or humans [26, 27].
Neither FRDA patients, or healthy controls noticed adverse
effects due to tocotrienol consumption. The tocotrienol
mixture was designed by Ambrosialab s.r.l., a spin-off com-
pany of the University of Ferrara, Italy. It is a Palm Oil (Elaeis
Guineensis) phytocomplex, prepared for the purposes of the
study, as soft gel capsule formulation and labeled as OXI-3
(internal reference name ALAB103). It is composed by to-
cotrienols and tocopherols in the enantiomerically pure nat-
ural form (total tocotrienol and tocopherol: 256mg/g,
of which D-tocotrienol is 197mg/g and D-tocopherol is
59mg/g).
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2.3. Blood Mononuclear Cell Isolation. Venous blood (15mL)
from FRDA patients and controls was collected in Na-EDTA
vacutainers and centrifuged 10min at 800×g, in order to
separate plasma, whichwas used for others studies.The blood
was then diluted 1 : 1 with phosphate buffered saline (PBS),
layered over HISTOPAQUE-1077 (Sigma, St. Louis, MO) and
centrifuged 35min at 453 g. Mononuclear cells were removed
from the gradient interface and washed three times with PBS.
Themononuclear cell pellet was dissolved with 1mL of Trizol
reagent (Invitrogen, Milan, Italy) and stored at −80∘C before
RNA extraction.
2.4. RNA Extraction and cDNA Synthesis. Total RNA was
extracted from the Trizol suspension following the manu-
facturer’s instructions and the paper by Chomczynski and
Sacchi [28]. RNA quality and cDNA synthesis was assessed as
previously described [29]. Briefly, RNA quality wasmeasured
by evaluation of 28S and 18S rRNA band sharpness after
denaturing electrophoresis. Genomic DNA contamination
was removed by digestion with RNase-free Deoxyribonu-
clease I (DNase I) (Amplification Grade DNase I, Sigma-
Aldrich, St. Louis, MO), and its absence was assessed by
PCR analysis using specific primers for HSP70 promoter
(left primer: cgccatggagaccaacaccc; right primer: gcggttccct-
gctctctgtc). RNA purity and concentration were measured
by spectrophotometer (Ultrospec 3000, Pharmacia Biotech,
Cambridge, UK).
Equal amounts of total RNA were reverse transcribed
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA) following the manufacturer’s instructions.The
cDNA thus obtained was stored at −20∘C and used for
semiquantitative and qRT-PCRs.
The amount of protein recovered following Trizol extrac-
tionwas insufficient for analysing frataxin protein expression.
2.5. Primer Design. Specific primer sequences for frataxin
isoforms, for PPARG, and for two housekeeping genes, beta-
actin and GAPDH, were designed with the help of two freely
available software tools Primers3 and Amplify.
Figure 1(a) shows the cDNA frataxin isoforms and
their respective primer sequences. In order to discriminate
between FXN-1 and FXN-2 isoforms, the primer pairs shared
the left primer, while the right primer was designed in the
precise site where the two isoforms differ (i.e., in the region
where the FXN-2 isoform has 8 bp insertion). FXN-3 primers
were designed in the cDNA region following nucleotide 702.
Primer sequences, summarized in Table 1 of supplemen-
tary data (see Supplementary Material available online at
http://dx.doi.org/10.1155/2013/276808), were purchased from
Sigma-GENOSYS (Sigma-Aldrich). To verify primer speci-
ficity, PCR products were subjected to both agarose gel
electrophoresis and amelting curve analysis.Moreover, FXN-
1 and FXN-2 primer specificity were evaluated by enzymatic
digestion of PCR products obtained with semi-quantitative
PCR.
2.6. Semiquantitative Polymerase Chain Reactions (PCR).
PCR analysis was performed using a Taq PCR core kit
FXN-1
FXN-2
FXN-3
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1
1
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(b) Enzymatic digestion of FXN-1 and FXN-2 PCR
products
Figure 1: (a) A representative scheme of frataxin isoform cDNAs
and primer sequences. Frataxin isoform 1 (FXN-1) and isoform 2
(FXN-2) share the left primer sequence, while the right primer was
specific for each isoform. Frataxin isoform 3 (FXN-3) right primer
sequence was designed in the region downstream the 702 base pair.
(b) Enzymatic digestion of FXN-1 and FXN-2 PCR products. A rep-
resentative polyacrylamide gel electrophoresis (10%) of FXN-1 and
FXN-2 PCR products digested or undigested with BstNI restriction
enzyme. Lane 1: DNA ladder; lane 2: undigested FXN-1 PCR prod-
uct; Lane 3: BstNI digested FXN-1 PCR product; lane 4: undigested
FXN-2 PCR product; lane 5: BstNI digested-FXN-2 PCR product.
(Qiagen S.r.l., Milan, Italy), according to manufacturer’s
instructions. PCR conditions were as follows: a denaturing
stage at 95∘C for 5min, 40 cycles at 95∘C for 50 s, 62.5∘C for
50 s, 72∘C for 10min, and a final stage extension at 72∘C for
10min. Positive and negative controls were used to check for
contamination and unspecific amplifications. PCR products
were analyzed on 2.5% agarose gel stained with ethidium
bromide at 0.5mg mL−1 after one hour of running at 70mV.
2.7. Enzymatic Digestion of FXN-1 and FXN-2 PCR Products.
FXN-1 and FXN-2 PCR products, 126 bp and 133 bp, respec-
tively, were digested with BstNI endonuclease (New England
Biolabs, Milan, Italy), taking into account that its restriction
site (5󸀠 CCWGG 3󸀠 and 3󸀠 GGWCC 5󸀠) is found exclusively
in the FXN-2 PCR product. To this purpose, FXN-1 and
FXN-2 PCR products were incubated with 1X NEB Buffer
2, 1mM BSA, and 1X BstNI in a final reaction volume of
20𝜇L. The digestion was carried out at 60∘C for 90min. The
digested fragments were separated by electrophoresis on 10%
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(b) qRT-PCR expression of frataxin isoforms
Figure 2: (a) Semiquantitative PCR analysis of frataxin isoforms in a control subject. Equal amount of a control subject cDNA was used for
FXN-1, FXN-2, and FXN-3 semiquantitative PCR analysis. PCR products were run in an agarose gel electrophoresis (2.5%). M: DNA ladder;
NC: negative control. (b) qRT-PCR expression of frataxin isoforms. Frataxin isoform mRNA expression was analyzed by qRT-PCR in five
healthy subjects (Ctr) and in five FRDA patients before (white columns) and after (grey columns) two-month tocotrienol supplementation.
Data were normalized for two housekeeping genes, beta-actin and GAPDH; for each gene target, the normalized expression value of one
control subject arbitrarily chosen was set to 1, and all other gene expression data were reported to that sample. Data are expressed as mean
of technical triplicates ± SD and analyzed by ANOVA. Following tocotrienol supplementation, FXN-3 mRNA increased 3.49-fold in FRDA
patients (𝑝 ≤ 0.00000000342).
polyacrylamide gel along with undigested samples and were
visualized by ethidium bromide staining.
2.8. Quantitative RT-PCR Analysis and Statistical Analysis.
Quantitative RT-PCR was performed in a Bio-Rad CFX96
real-time thermal cycler using the SsoFast EvaGreen Super-
mix (Bio-Rad Laboratories, Hercules, CA). Using CFXMan-
ager Software (Bio-Rad Laboratories, Hercules, CA) and
qbaseplus (http://www.biogazelle.com/), data were analyzed
with the 2−ΔΔCT method [30], taking into account the effi-
ciency of the real-time PCR reaction between 95% and 105%
[31]. Quantitative RT-PCR evaluations were repeated at least
twice. Data were evaluated by ANOVA test.
2.9.Modelling of Human FXN-2 and FXN-3 and of the Human
NFS1/ISCU Complex. In order to build the 3D model of the
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Figure 3: qRT-PCR expression of PPARG. Peroxisome proliferator-
activated receptors-𝛾 (PPARG) mRNA expression was analyzed
by qRT-PCR in five healthy subjects (Ctr) and in five FRDA
patients before (white columns) and after (grey columns) two-
month tocotrienol supplementation. Data were normalized for two
housekeeping genes, beta-actin and GAPDH; for each gene target,
the normalized expression value of one control subject arbitrarily
chosen was set to 1, and all other gene expression data were reported
to that sample. Data are expressed as mean of technical triplicates ±
SD and analyzed by ANOVA.
human protein isoforms FXN-2 and FXN-3 (the targets),
FXN-1 was adopted as a template. The human frataxin
mature form (FXN-1) is determined at 1.80 A˚ (Swiss-Prot:
FRDA HUMAN; PDB code 1EKG [8]). Pairwise align-
ment of the different FXN-2 and FXN-3 with FXN-1 was
generated with ClustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/) in an expert-driven mode, considering also the
alignment of the secondary structure motifs to those of the
template. Secondary structure predictionwas performedwith
PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/). The different
models were computed with Modeller version 9.8 [32]. For
a given alignment, 20 model structures were built and
evaluated with the programs PROCHECK [33] and ProSa
[34] for stereo chemical and energetic validation, respectively,
retaining only the model that better met the restrictions of
both programs. Structural overlapping between FXN-1, FXN-
2, and FXN-3, respectively, was done with MultiProt 3D
(http://bioinfo3d.cs.tau.ac.il/MultiProt/).The 3D structure of
the human complexNFS1/ISCUwas computed on the basis of
the available template of E. coli ISCS/ISCU (PDB code: 3LVL)
[35]. The complex was computed with the same procedure
described above. To calculate the tetrameric form, consisting
of 2 chains of NFS1 and 2 chains of ISCU, the PDBePISA
server (http://www.ebi.ac.uk/msd-srv/prot int/)was adopted
to predict the protein interfaces and consequently the likely
quaternary structure of the protein complex.
2.10. Docking of the Different Human Frataxin Isoforms
on the NSF1/ISCU Complex. Rigid molecular docking of
the different human frataxin isoforms on the NSF1/ISCU
complex was performed with Autodock version 4.2 Release
4.2.3 [36]. Five different atom-specific affinity maps were
generated with autogrid4, (A, NA, C, OA and N) in addition
to electrostatic and desolvation maps. The grid was centered
on each ligand, consisting of 126 points (XYZ) and spacing
of 0.475 A˚ that allows an unconstrained roto-translation of
the ligand. For each isoform, twenty-five independent jobs
were submitted by the Lamarckian genetic algorithm, with
an initial population of 150 conformations, a cutoff of 27,000
generations, and with rates of mutation and crossover set to
0.02 and 0.8, respectively.Thefinal solutionwas characterized
by the lowest binding energy.
3. Results
3.1. FXN-1 and FXN-2 Primer Sequence Specificity. Hav-
ing confirmed the primer specificity by both agarose gel
electrophoresis and melting curve analysis (not shown),
FXN-1 and FXN-2 PCR products, which differed in 8 bp
(Figure 1(a)), were digested with the BstNI restriction
enzyme. BstNI cleaves FXN-2 PCR product (133 bp) in two
fragments of 109 bp and 24 bp and leaves the FXN-1 PCR
product uncut. Undigested and digested fragments were
separated on polyacrylamide gel (Figure 1(b)). As expected,
FXN-1 PCR product restricted with BstNI was undigested,
while the 109 bp fragment shows the digestion operated by
BstNI.
3.2. Semiquantitative PCR. To compare the relative basal level
of frataxin isoform gene expression, a semi-quantitative PCR
was performed in a cDNA sample from a healthy control.
The same amount of cDNAwas amplified in separate wells by
using the primer pairs specific for the three frataxin isoforms.
The PCR products were then compared in a 2.5% agarose
gel. As shown in Figure 2(a), FXN-1 is way more expressed
than FXN-2 and FXN-3. These results were also confirmed
by qRT-PCR, by comparing the number of cycles of the
three isoforms after normalizing versus the housekeeping
genes. Such analysis was carried out bymeans of the qbaseplus
software. In particular, in healthy controls before treatment,
we found that FXN-2 and FXN-3 mRNA expression was
4.72% and 2.47% of FXN-1, respectively. Our data are in
agreement with those reported in the literature [4, 6].
3.3. Quantitative RT-PCRGene Expression. Frataxin isoforms
and PPARG gene expressionwere evaluated in FRDApatients
and healthy control before and after tocotrienol treatment
using qRT-PCR. As expected, all frataxin mRNA isoforms
were less expressed in FRDA patients with respect to control
subjects (Figure 2(b)), in line with data reported in literature
[3]. In particular, in FRDApatientsFXN-1,FXN-2, andFXN-3
mRNAswere, respectively, 24.6%, 0.71%, and 0.11% compared
to FXN-1 of healthy subjects.
FRDA patients treated with tocotrienol for two months
showed 3.49-fold increase of FXN-3 mRNA compared to
FRDA patients before tocotrienol supplementation (𝑝 ≤
0.00000000342) (Figure 2(b)), while FXN-1 and FXN-2
expression did not change after tocotrienol treatment
(Figure 2(b)). Although tocotrienol treatment did not restore
frataxin isoform mRNA expression to the levels of control
subjects, in FRDA patients, we found an increase of 16%
of total frataxin mRNA expression compared to FRDA
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Figure 4: Structural comparison of human FXN-1 with FXN-2 and FXN-3. Sequence and structural alignment of FXN-1 (1EKG, depicted in
blue) with the computed 3Dmodels of FXN-2 and FXN-3 (colored in green and red, resp.).The secondary structure of FXN-1 is also reported
along the structural alignment (helices: red line; beta sheets: yellow arrow). Functional residues of the anionic patch and residues involved in
protein stability are highlighted in black and orange, respectively, and are conserved in all the isoforms.
patients before treatment. Tocotrienol treatment did not
affect frataxin isoform gene expression in healthy controls.
Figure 3 shows themRNAabundance of PPARG in FRDA
patients and healthy controls before and after tocotrienol
treatment. PPARG gene expression displayed a trend towards
increase upon tocotrienol supplementation, although the
increasewas not statistically significant due to high variability
within the groups.
3.4. Modelling of the Human FXN-2 and FXN-3 and of the
Human NFS1/ISCU Complex. The 3D model of the human
FXN-2 and FXN-3 was built by adopting the structure of
FXN-1 as a template. Figure 4 shows the structural over-
lapping between isoform1, 2, and 3 and the corresponding
structural alignment. Root mean square deviations (RMSD),
as calculated on the protein backbone, are 1.31 A˚ and 1.32 A˚
among FXN-1 and FXN-2 and FXN-1 and FXN-3, respec-
tively. FXN-1 and FXN-3 share identical residues with the
exception of the C-terminus alpha helix. However, the two
isoforms conserve residues that are correlated to the protein
function: 12 charged residues involved in the anionic patch
(E92, E96, E100, E101, E104, E108, E111, D112, D115, E121, D122,
andD124) and 11 residues involved in the stability (T133, T142,
V144, N146, Q148, Q153, I154, W155, L156, S157, and R165),
which are well conserved in sequence, secondary, and tertiary
structures. FXN-2 shares also 72 identical residues with FXN-
1 in the functional region. In the C terminal portion, the two
sequences differ in residue composition; however, residues in
this part of the protein are enough to cover the C-terminus
alpha helix of FXN-1.
The 3D structure of the human complex NFS1/ISCU
was computed on the basis of the available template of E.
coli ISCS/ISCU (PDB code: 3LVL) [35]. Sequence identity
between bacterial and human counterparts is 59% for the
ISCS/NFS1 domains and 75% for the ISCU/ISCU domains.
The values of sequence identity ensure that modelling results
a reliable 3D structure (Figure 5).
3.5. Docking of Human FXN-1, FXN-2, and FXN-3 to the
Human NFS1/ISCU Complex. Mature human frataxin phys-
ically interacts with the Fe-S cluster biosynthesis machinery
components NFS1 and ISCU [14]. Here, we investigated the
binding capability of FXN-1, -2 and -3 to the complex in order
to understand whether functional interaction is similar in the
three isoforms. To this purpose, we modelled on the iron-
sulfur assembly complex from E.coli the human counterparts
and computed the 3D structure of the human tetrameric
complex (see Figures 5(a) and 5(b)).
The anionic patch of frataxin is involved in the interaction
with basic residues of NFS1 (R218, R219, R221, and R223,
Figure 5(b)). The residues on the frataxin beta-sheets, in
particular N146, W155, and R165, have been proven to be
directly involved in the interaction with ISCU and also in
protein stability (Figure 5(c)) [14, 37]. After docking of the
FXN-3 model into the same complex, we found that all these
relevant interactions are conserved (see zoomed portion of
BioMed Research International 7
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Figure 5: Docking of human FXN-1, FXN-2, and FXN-3 on the human tetrameric NFS1/ISCU complex. (a)The human iron-sulfur assembly
complex was modeled adopting the E. coli counterpart as a template (PDB code: 3LVL). The NFS1/ISCU complex includes two copies of
ISCU (surface representation in purple) and two copies of NFS1 (surface in cyan and yellow, resp.). The backbone of the three frataxin
isoforms is depicted in blue (FXN-1), in green (FXN-2), and in red (FXN-3). The three backbones overlap with a pairwise root mean square
deviation (RSMD) of about 1.3 A˚. (b) Important residues essential for functional interaction are conserved in all isoforms and highlighted
in black. Relevant interactions on the complex are highlighted in orange. Basic residues of NFS1 involved in the interaction with the anionic
patch of frataxin (R218, R219, R221, and R223) are colored in light green. (c) Zooming on conserved residues among human frataxins was
experimentally proven in yeast and humans to play a critical role in the interaction with the ISCU complex: W155 N146 and R165 (R161 in
FXN-2 and FXN-3).
Figures 5(b) and 5(c)), thus corroborating the notion that
the function of FXN-3 is preserved despite the lack of the
C-terminus alpha helix. The docking of FXN-2 is also shown
for the sake of comparison.
4. Discussion
Although frataxin role is not completely understood, frataxin
deficiency has been suggested to sustain the increased oxida-
tive stress, which is central in the pathogenesis of FRDA [38].
To date, there is still no effective cure for FRDA. As recently
reported [39], one of the current therapeutic strategies in
FRDA disease is the development of molecules aimed at
increasing frataxin expression. Despite encouraging in vitro
preliminary results, the effectiveness of these compounds as
therapeutic agents requires more detailed studies to exclude
unspecific and side effects in FRDA patients. Another thera-
peutic approach is aimed at counteracting oxidative stress. In
this perspective, we focused our attention on tocotrienol, a
potent antioxidant that is able to decrease a number of oxida-
tive stress markers in FRDA patients (M. Marini, submitted
paper). This encouraging result prompted us to investigate
whether tocotrienol could modulate the expression of the
different isoforms of frataxin mRNA. As previously reported,
humanmononuclear cells as well as fibroblasts, although they
do not correspond to the cells affected in FRDA patients,
represent a suitable in vitro model to study the expression of
an ubiquitously expressed protein such as frataxin [5].
Here we report for the first time that tocotrienol induces,
exclusively in FRDA patients, a significant 3.49-fold increase
of the FXN-3 isoform mRNA (Figure 2(b)). Such increase is
specific, since it does not affect FXN-1 or FXN-2 (Figure 2(b));
therefore, the underlying mechanism(s) should include both
an enhancement of gene transcription and/or of mRNA half-
life and a regulation of differential splicing. No apparent
relationship was found between the number of triplet repeats
and frataxin expression and/or the amount of the tocotrienol-
induced FXN-3 increase. Although we are aware that the
increase in FXN-3 gene expression should be confirmed by
an analysis of protein expression, at present, it is not possible
to measure protein expression of the FXN-3 isoform because
a specific antibody is not available.
Marmolino and coworkers [40] showed that peroxisome
proliferator-activated receptors-𝛾 (PPARG) is involved in the
upregulation of mRNA and protein frataxin expression in
cell lines from FRDA patients. Tocotrienols both increase
mRNA expression of PPAR receptors 𝛼, 𝛾, and 𝛿 and, by
directly binding their LBDs, induce an increase of their
transcriptional activities [41]. PPARG gene expression was
measured in both treated and untreated subjects in order
to evaluate whether tocotrienol enhancement of FXN-3 was
mediated by an increase in PPARG expression. The high
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variability in PPARG expression among subjects did not allow
a significant conclusion to be reached (Figure 3); however,
as already pointed out, tocotrienol may activate PPARG
transcriptional activities in a way that is independent of its
increase [41].
On the other hand, tocotrienol may promote FXN-3
mRNA expression through signalling pathways alternative to
PPAR, as tocotrienols are able to modulate different targets at
transcription, translation, and posttranslation levels [23].
Whether the tocotrienol-induced increase in FXN-3
expression is biologically relevant obviously depends on the
ability of the FXN-3 isoform to perform its tasks. To our
knowledge, no functional and structural studies have been
carried out for the FXN-3 isoform; therefore, we performed
a structural analysis by means of bioinformatics tools. FXN-
3 and FXN-1 share a 93% protein sequence identity; from
the comparison of their sequences, the residues known to be
correlated with protein function [8] and with stability [37]
were found to be well conserved in sequence, secondary, and
tertiary structures (Figure 4).
By modeling of the iron-sulphur assembly complex from
E. coli and computing from it the 3D structure of the human
tetrameric complex, we found that all relevant interactions
are conserved between FXN-1, FXN-2, and FXN-3 (see
zoomed portion of Figure 5), with comparable docking bind-
ing energy. Despite the partial or total lack of the C-terminus
alpha helix, these data show that both FXN-2 and FXN-3
not only have an identity of structure compared to FXN-1
but also have the same ability to interact with NFS1/ISCU.
These bioinformatics data show for the first time that both
FXN-2 and FXN-3 may have a biological function and can
be considered a starting point for future studies aimed at
confirming the function of both FXN-2 and FXN-3 isoforms
by using the purified protein.
5. Conclusions
Our results demonstrate, for the first time, (i) that tocotrienol
induces in FRDA patients the upregulation of the FXN-3
mRNA isoform and (ii) that FXN-3 and FXN-2 proteins share
the same 3D structure as FXN-1 and are apparently able to
complex with NFS1/ISCU, thus suggesting that they may play
the same functions. Since basal level of FXN-3 is very low,
its 3.49-fold increase in tocotrienol-treated patients was not
enough to reach frataxin mRNA amounts enabling normal
cellular functions [3].
The mechanism by which tocotrienol enhances FXN-
3 mRNA levels should be further investigated. In fact, it
has been reported that SRF and TFAP2 iron-dependent
transcription factors regulate frataxin expression [42] and
that tocotrienol stimulates PPARG activity dose dependently
[41]. Therefore, we are planning to evaluate in FRDA cell
lineswhether higher tocotrienol concentrations could further
enhance frataxin mRNA levels, in PPARG-dependent or
independent manner. Cell culture studies will also allow the
evaluation of variations in frataxin protein levels, which is
almost impossible to perform inmononuclear cells, which are
poor frataxin producers. This will hopefully enable the use of
tocotrienol not only as antioxidant therapy but also as inducer
of frataxin expression.
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